SCHEDULE: Janus Henderson Reports 4.8% Stake in Bicara Therapeutics

Janus Henderson Group Ltd. has disclosed beneficial ownership of 4.8% of Bicara Therapeutics Inc. common stock, as of June 30, 2026.

Summary

• Janus Henderson Group Ltd. (JHG) has filed an amendment to its Schedule 13G, reporting beneficial ownership of 3,171,015 shares of Bicara Therapeutics Inc. common stock.
• This holding represents 4.8% of the class of securities.
• The filing indicates that the shares are held by various Asset Managers under JHG, which exercise investment and/or voting discretion on behalf of their clients.
• JHG disclaims beneficial ownership of dividends and proceeds from the sale of these securities, as these rights belong to the Managed Portfolios.
• The reporting date for this ownership is June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership percentage and does not contain operational or financial performance updates.

Positives

• Janus Henderson Group Ltd. has a significant investment in Bicara Therapeutics Inc., indicating confidence from a major asset manager.
• The filing clarifies the beneficial ownership structure, attributing it to various managed portfolios rather than JHG directly.

Negatives

• The filing does not provide any new operational or financial performance data for Bicara Therapeutics Inc.
• The disclosure is an amendment to a previous filing, suggesting a change in ownership percentage or reporting status rather than a new development.

Risks

• The filing does not explicitly mention any risks associated with Bicara Therapeutics Inc. or the investment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Bicara Therapeutics Inc.'s future performance.

Management Comments

• Janus Henderson Group Ltd. disclaims any ownership associated with the right to receive dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios.
• Kristin Mariani, Head of North America Compliance, certifies that the information is true, complete, and correct.

Industry Context

StockSavvy.ai notes that this filing is a routine Schedule 13G disclosure, indicating a significant institutional investor's stake. Such filings are common in the biotechnology sector as companies advance through clinical trials and seek funding.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may influence investor sentiment and potentially impact share price, though no new performance data is provided.
• Management of Bicara Therapeutics Inc.: The continued investment by Janus Henderson Group Ltd. may be viewed as a positive signal of confidence in the company's strategy and prospects.

Next Steps

• Janus Henderson Group Ltd. will continue to file amendments to Schedule 13G as required by regulatory authorities.
• The Asset Managers will continue to exercise investment and/or voting discretion on behalf of their clients.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Janus Henderson Group, Bicara Therapeutics, investment adviser, common stock, asset manager